Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells - A clinical trial
Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells - A clinical trial
复制标题
DOI：
10.1097/01.cji.0000171291.72039.e2
复制
发表时间：
2005-09-01
影响因子：
3.9
通讯作者：
Chen, MF
中科院分区：
文献类型：
--
作者：
Lee, WC;Wang, HC;Chen, MF
肝细胞癌（HCC）是一种常见且进展迅速的恶性肿瘤。目前晚期HCC的治疗选择有限。这项基于树突状细胞（DC）的免疫治疗肝癌的临床研究纳入了31例晚期肝癌患者。从外周血单核细胞增殖的DC用自体肿瘤裂解物脉冲以治疗HCC。前14名患者接受了每周间隔静脉注射DC疫苗的五个疗程的脉冲治疗。其他17名患者在最初的脉冲治疗后接受每月加强疫苗接种。在31例患者中，4例（12.9%）对DC疫苗接种表现出部分应答。17例患者（54.8%）病情稳定。10例患者（32.3%）出现疾病进展。所有31例患者的总体1年生存率为40.1 ± 9.1%。接受脉冲治疗和加强治疗的患者的1年生存率高于单独接受脉冲治疗的患者（63.3 +/- 12.0% vs. 10.7 +/- 9.4%; P < 0.001）。在这项试验中，晚期HCC的DC疫苗接种是安全的。DC疫苗接种前后肝功能检查无差异。这项临床试验的结果表明，DC疫苗接种是一种安全的HCC治疗方法。脉冲DC疫苗接种后加强免疫可以为晚期HCC患者提供比仅脉冲DC疫苗接种更好的临床存活率。需要进一步的研究来提高这种治疗方法的疗效。
Hepatocellular carcinoma (HCC) is a common and rapidly progressing malignancy. Current treatment options for advanced HCC are limited. This clinical study of dendritic cell (DC)-based immunotherapy for HCC enrolled 31 patients with advanced HCC. DCs, propagated from peripheral blood monocytes, were pulsed with autologous tumor lysates to treat HCC. The first 14 patients underwent pulsed therapy with five courses of DC vaccination intravenously at weekly intervals. The other 17 patients underwent monthly boost vaccinations after the initial pulsed therapy. Among the 31 patients, 4 (12.9%) exhibited partial response to DC vaccination. Seventeen patients (54.8%) had stable disease. Ten patients (32.3%) had progressive disease. The overall 1-year survival rate of all 31 patients was 40.1 +/- 9.1%. The patients treated with pulsed and boosted therapy had better 1-year survival rates than those treated by pulsed therapy alone (63.3 +/- 12.0% vs. 10.7 +/- 9.4%; P < 0.001). In this trial, DC vaccinations for advanced HCC were safe. Liver function tests showed no difference before and after DC vaccinations. The results of this clinical trial indicate that DC vaccination is a safe treatment for HCC. Pulsed DC vaccination followed by boosters can provide better clinical survival for advanced HCC patients than pulsed DC vaccination only. Further studies are needed to increase the efficacy of this therapeutic approach.